A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Kodiak Sciences Inc. KOD

Mixed (early) broader-coverage candidate · Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various con

On FrontierLab's discovery record since 2026-08-03 (9 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-29), not the curated Frontier signal.

⚡ Surfaced on a price move — momentum is where to look, not a buy signal. The move that surfaced this name does not make it a good entry.

⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.

Key quality signals

Revenue growth (YoY)	—
Gross margin	—
Gross profits / assets	0
Rule of 40	—
Net margin	—
Cash runway (months)	9.5
PEG	—
Price / sales	—

Quality checklist

~ Capital efficiency
~ Share dilution — 18.7%

Fundamentals — snapshot as of 2026-09-29

Stage	Early
Share issuance (YoY)	18.7% · heavy issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-4.19
Burn multiple	—
Gross-margin trend (pts)	—
Cash / assets	0.49
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-13

Momentum context — a snapshot from 2026-09-29, not current

Price at surface	$89.92 (as of 2026-09-29)
52-week range	$10.94 – $95.77
% off 52-wk high	-6.1%
RSI (14)	90
Relative volume	13.9×

Risk flags

Cash runway ~10 months at current burn — a raise (and dilution) looks likely.Heavy dilution (~19%/yr) — top-decile share issuers have historically underperformed.Parabolic one-day spike (+178%) in the last month — extreme single-day moves tend to mean-revert.Volume 13.9× normal alongside the move — attention-crowded names tend to reverse over the following weeks.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-29 (end-of-day). How grades are computed →